GlassScriptPhysician profile
Cassidy R Cooper
NPI 1275099475
$5,815.36
in general payments reported to CMS, 2019-2025
34 companies · $2,354 in 2025
The $2,354 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $10.01 · 2023: $1,425 · 2024: $2,026 · 2025: $2,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,720 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,720.35 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $841.20 | 2023-2025 | Evenity, Repatha, Prolia |
| Sanofi-Aventis U.S. LLC | $787.86 | 2023-2025 | |
| Novo Nordisk INC | $579.49 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $430.13 | 2023-2025 | Freestyle Libre, Freestyle Libre 3 |
| Beta Bionics, INC. | $372.40 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $369.28 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Lilly USA, LLC | $308.83 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $224.86 | 2024-2025 | Korlym |
| Neurocrine Biosciences, INC. | $218.71 | 2025 | |
| Tandem Diabetes Care, INC. | $204.86 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $189.06 | 2025 | Twiist |
| Radius Health, INC. | $131.21 | 2024-2025 | Tymlos |
| Abbvie INC. | $115.83 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $113.04 | 2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.98 | 2023-2025 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $110.19 | 2023-2025 | Isturisa, Signifor Lar |
| Insulet Corporation | $105.59 | 2023-2024 | Omnipod |
| Mannkind Corporation | $101.06 | 2025 | |
| Novartis Pharmaceuticals Corporation | $51.80 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $48.27 | 2025 | Imcivree |
| Amneal Pharmaceuticals LLC | $46.68 | 2024 | Unithroid |
| Averitas Pharma INC. | $44.61 | 2024-2025 | Qutenza |
| Kyowa Kirin, INC. | $43.46 | 2023-2025 | Crysvita |
| Alnylam Pharmaceuticals INC. | $40.71 | 2024-2025 | Givlaari |
| Ascendis Pharma Endocrinology INC | $37.82 | 2024-2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $37.60 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $32.39 | 2023 | Steglatro, Steglujan |
| Alexion Pharmaceuticals, INC. | $26.62 | 2025 | Strensiq |
| Regeneron Healthcare Solutions, INC. | $18.06 | 2025 | Evkeeza |
| Amryt Pharma Holdings LTD | $17.66 | 2023 | Mycapssa |
| Pfizer INC. | $16.74 | 2024 | |
| Almatica Pharma LLC | $13.63 | 2024 | Teriparatide |
| Kowa Pharmaceuticals America, INC. | $12.72 | 2023 | Livalo |
| Genentech USA, INC. | $10.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassidy Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.